OPKO Health, Inc. (OPK) Stock

OPKO Health, Inc. (OPK) is a Healthcare stock trading at $1.48 (as of 2026-08-21), with a market capitalization of $1.10B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

OPKO Health, Inc. operates diagnostics and pharmaceuticals businesses. In diagnostics, it provides laboratory testing services through BioReference Laboratories and offers related services such as molecular, pathology, women’s health, and other specialized tests, along with point-of-care blood test and prostate cancer testing services. Its pharmaceutical segment develops and markets treatments including Rayaldee and other investigational therapies, serving patients and healthcare providers.

Understand OPKO Health, Inc.: how it makes money

OPKO Health runs a diagnostics business through BioReference Laboratories, providing lab testing services (such as molecular diagnostics and pathology) sold to physician offices, clinics, hospitals, employers, and governmental units, and it also has a pharmaceuticals business that generates revenue from pharmaceutical segment activities including product sales and transfer of intellectual property.

The companys profit is structurally driven by whether Diagnostics segment revenue can cover its Diagnostics segment costs, because in the latest quarter the company reported a negative operating margin (-41.1%) despite a positive gross margin (36.8%).

Revenue by segment (latest quarter)
Diagnostics	$0.1B
Pharma	$0.0B

Business quality (Weak): Segment labels align to the companys two main businesses (Diagnostics and Pharmaceuticals), but the provided segment revenue candidates do not perfectly reconcile to total revenue (0.1B), so segment-level detail should be treated as directionally informative.

Bull case

Positive gross margin: For the quarter ended 2026-03-31, gross_margin_pct was 36.8%, indicating the company generated gross profit on its revenue base even though operating profit was negative.
Diagnostics is a key revenue driver: Diagnostics-related revenue is present in the provided segment revenue candidates (including Diagnostics revenue from services), supporting that BioReference Laboratories is a central part of the revenue mix.

Bear case

Operating losses: The company reported an operating_margin_pct of -41.1% for the quarter ended 2026-03-31.
Diagnostics costs pressure: Provided candidates show Diagnostics segment costs and expenses that are high relative to Diagnostics segment revenue (for example, Diagnostic Segment Costs and Expenses appears as 0.12B versus Diagnostic Segment Revenue appearing as low as 0.1B).

Valuation — source: SEC EDGAR (first-party)
Price	$1.48
Market Cap	$1.10B
EV / EBITDA	19.0
Price / Book	0.93
Price / Sales	1.87
FCF Yield	-12.2%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$606.88M
Net Margin	-37.2%
Revenue Growth (YoY)	4.3%
EPS Growth (YoY)	-94.7%
FCF Growth (YoY)	-46.4%

Financial Health — source: SEC EDGAR
Altman Z-Score	-0.26 (distress)
Piotroski F-Score	3/9 (weak)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.7
Industry P/E (Pharmaceutical Products)	17.2

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Insider Buys (12mo)	33
Top Institutional Holder	BlackRock Fund Advisors ($105.37M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Phillip Frost
Employees	2,997
Country	US
IPO Date	1995-11-02

Related Companies (Pharmaceutical Products; 8 comparable drugmakers)

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.